Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.

Kelly E DooleySachiko MiyaharaFlorian von Groote-BidlingmaierXin SunRichard HafnerSusan L RosenkranzElisa H IgnatiusEric L NuermbergerLaura MoranKathleen DonahueSusan SwindellsNaadira VankerAndreas H Diacon

Published in: American journal of respiratory and critical care medicine (2020)

Keyphrases

high dose
mycobacterium tuberculosis
pulmonary tuberculosis
stem cell transplantation
low dose
emergency department
adverse drug
hiv infected
electronic health record
drug induced